Clinical Trial Details

Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel

Categories (click each to see list of all clinical trials associated with that category): Cellular Therapy Support Service - CAR-T (ONC), Lymphoma/CLL (ONC)

Current Status: Open

Phase: N/A (Cancer Control)

Principal Investigator: Lunning, Matthew

Contact Information:
Sarah Snook


The objective of this study is to provide access to axicabtagene ciloleucel that is OOS for commercial release to subjects with an approved labeled indication. The outcome measure is: - Incidence of SAEs and deaths from informed consent to 30 days post infusion or early withdrawal.